Gan & Lee Pharmaceutical
- Company typePublic
- Founded1998
- HeadquartersBeijing, China
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Gan & Lee Pharmaceutical firmographics
Firmographics- Name
- Gan & Lee Pharmaceutical
- Legal name
- Gan & Lee Pharmaceuticals Co., Ltd.
- Website
- https://ganlee.com
- Company type
- Public
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Gan & Lee Pharmaceutical industry classification
Industry- Product category
- Insulin and Diabetes Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industries
- Insulin & Analog Biosimilars (HLAIAFAB), Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC)
Keywords
Where Gan & Lee Pharmaceutical is headquartered
LocationHeadquarters
- HQ city
- Beijing
- HQ country
- China
- HQ region
- Asia
Offices3 records
Markets served
Gan & Lee Pharmaceutical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Insulin Product Sales: Sales of six core insulin products including insulin glargine (Basalin/Ondibta), insulin lispro (Prandilin/Bysumlog), insulin aspart (Rapilin/Dazparda), premixed formulations, and human insulin. Products sold globally through partnerships and direct commercial relationships in 19 countries.
- Medical Device Sales: Sales of insulin delivery devices including reusable insulin injection pen (GanleePen) and disposable pen needle (GanleeFine), approved in multiple markets including FDA approval in 2020.
- Licensing and Milestone Payments: Out-licensing of innovative drug candidates including Bofanglutide. Receives upfront payments ($5M from JW Pharmaceutical), milestone payments (up to $76.1M total deal value with JW Pharmaceutical), and tiered royalties on net sales from licensees.
- Technology Transfer and Supply Agreements: Long-term technology transfer agreements with guaranteed supply commitments, such as the 10-year agreement with Fiocruz/Biomm in Brazil with cumulative orders of no less than RMB 3 billion.
Go-to-market motion1 record
Distribution channels6 records
Marketing channels8 records
Gan & Lee Pharmaceutical product offering
Product offeringCore offering
Gan & Lee Pharmaceuticals is a Chinese biopharmaceutical company that develops, manufactures, and commercializes recombinant insulin analog products and GLP-1 receptor agonists for diabetes and obesity treatment. The company offers a portfolio of six core insulin products (insulin glargine, insulin lispro, insulin aspart, premixed formulations, and human insulin) along with reusable insulin pens and disposable pen needles, marketed globally through licensing partners and distribution agreements across 23 registered countries.
Product overview
Gan & Lee Pharmaceuticals is a biopharmaceutical company and China's first to master industrial-scale manufacturing of recombinant insulin analogs. The company offers six core insulin products: Basalin® (insulin glargine, long-acting), Prandilin™ (insulin lispro, fast-acting), Rapilin® (insulin aspart, fast-acting), Prandilin™25 (premixed lispro), Rapilin®30 (insulin aspart 30), and Similin®30 (human insulin). These are complemented by two approved medical devices: GanleePen (reusable insulin pen) and GanleeFine® (disposable pen needle). The pipeline includes investigational products: GZR4 (once-weekly basal insulin in Phase 3), Bofanglutide/GZR18 (bi-weekly GLP-1 RA in Phase 3), GZR102 (once-weekly insulin/GLP-1 combination in Phase 2), and GZR101 (novel premixed insulin in Phase 2). Products span long-acting, rapid-acting, and premixed insulin categories, covering diabetes treatment from basic therapy to complex glycemic management.
Differentiator
Problem solved
Functional benefit
Brands
- Basalin: Insulin Glargine Injection - long-acting insulin analog (also marketed as Basalin in China, Ondibta in EU)
- Prandilin
- Rapilin
- Prandilin 25
- Rapilin 30
- Similin
- GanleePen
- GanleeFine
- GLARGILIN
Products and services
- Insulin Glargine Injection (Basalin® / Ondibta®) Long-acting basal insulin analog used for glycemic control in adults and children with type 1 and type 2 diabetes. Provides once-daily dosing with stable basal insulin coverage.
- Insulin Lispro Injection (Prandilin™ / Bysumlog®) Rapid-acting insulin analog with onset of 10-15 minutes, peak effect at 30-70 minutes, and duration of 2-5 hours for postprandial blood glucose control in patients with diabetes mellitus.
- Insulin Aspart Injection (Rapilin® / Dazparda®) Rapid-acting insulin analog with onset of 10-20 minutes, peak effect at 1-3 hours, and duration of 3-5 hours for mealtime glucose control in patients with diabetes mellitus.
- Premixed Insulin Lispro (Prandilin™ 25) Mixed protamine zinc lispro injection (25R) that combines rapid-acting and intermediate-acting insulin components in a single formulation for convenient dosing.
- Insulin Aspart 30 Injection (Rapilin® 30) Premixed insulin containing 70% insulin protamine crystals and 30% soluble insulin aspart for glycemic control in patients with diabetes.
- Human Insulin (Similin® 30) Mixed protamine human insulin injection (30R) for the treatment of patients with diabetes mellitus requiring insulin therapy.
- GanleePen (Reusable Insulin Injection Pen) Reusable insulin injection pen designed for the subcutaneous delivery of insulin from cartridges, used by patients with diabetes for self-administration of insulin therapy.
- GanleeFine® (Disposable Pen Needle) Disposable pen needle for subcutaneous insulin injection, used with insulin pens for diabetes management. Approved by the US FDA in 2020.
Quantifiable outcome
- HbA1c reduction of -1.45% vs -1.22% for insulin glargine U100 in SUPER-1 trial
- +4 more outcomes
Companies that use Gan & Lee Pharmaceutical
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
Gan & Lee Pharmaceutical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Gan & Lee Pharmaceutical partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, minor and flagship.
- JW PharmaceuticalcoreExclusive licensing agreement for development and commercialization of Bofanglutide Injection in South Korea. Gan & Lee receives $5 million upfront payment, up to $76.1 million in milestone payments, and tiered royalties on net sales. Total potential deal value of $81.1 million. JW Pharmaceutical leads development, regulatory approval, and commercialization for type 2 diabetes, obesity, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis indications.
- SandozcoreDevelopment, commercialization and license agreement for three insulin biosimilars (Insulin Glargine, Insulin Lispro, and Insulin Aspart). Sandoz has rights to commercialize biosimilars upon regulatory approval in Europe and other key territories. Gan & Lee responsible for manufacturing and supply. This partnership reinforces Sandoz's biosimilar footprint in diabetes care with Ondibta (biosimilar insulin glargine) receiving European Commission approval and launch expected early 2027.
- LupincoreExclusive licensing, supply, and distribution agreement for Bofanglutide (bi-weekly GLP-1 RA) in India. Lupin gains sole rights to commercialize and distribute the drug for type 2 diabetes and weight management. This partnership strengthens Lupin's diabetes portfolio while marking strategic entry into obesity treatment space targeting India's 174 million overweight adults.
- Brazilian Diabetes Society (SBD)minorCollaboration for participation in XXV Congresso da Sociedade Brasileira de Diabetes 2025. Joint booth combining product displays with interactive experiences. Partnership with Biomm to showcase insulin products and engage healthcare professionals at the congress.
- Fiocruzflagship10-year Technology Transfer and Supply Agreement with Fiocruz (public laboratory under Brazilian Ministry of Health) and Biomm for localized insulin manufacturing under Brazil's PDP project. Gan & Lee provides technology transfer for insulin glargine production while Fiocruz commits to long-term procurement of minimum RMB 3 billion over 10 years. This is the first Chinese pharmaceutical company to participate in Brazil's PDP project, enabling Brazil to establish domestic insulin manufacturing capability.
- Malaysian NPRA-Approved Local PartnersminorLocal pharmaceutical partners in Malaysia for insulin product registration and commercialization. Multiple products approved including insulin glargine (February 2025), insulin aspart 30 (March 2025), and insulin aspart cartridge (June 2025). Partnership demonstrates company's capabilities in global regulatory affairs and technology transfer for PIC/S regulatory standards.
- BiommflagshipBrazilian biopharmaceutical partnership established in 2014 for insulin glargine registration and commercialization. Biomm leverages local regulatory expertise and healthcare system knowledge for market entry. The partnership has expanded to include PDP project collaboration with Fiocruz for technology transfer and local manufacturing. Biomm conducts local filling of insulin glargine injection and delivers products to Fiocruz.
- Brazilian Ministry of HealthflagshipStrategic partnership for diabetes prevention and treatment cooperation. Minister Alexandre Padilha met with CEO Du Kai to enhance collaboration in diabetes care, foster innovation in diagnostic and therapeutic technologies, and exchange best practices in disease prevention. The Ministry expressed strong interest in Gan & Lee's biopharmaceutical manufacturing expertise and global supply chain management capabilities.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Gan & Lee Pharmaceutical competitors and assessment
Company assessmentEmerging players
- Ypsomed: Swiss manufacturer of pen injectors and autoinjectors used by many insulin and GLP-1 manufacturers. Comparable as an adjacent device supplier competing with Gan & Lee's GanleePen and GanleeFine franchise.
- MannKind Corporation: US-based company with inhaled insulin (Afrezza) and an endocrine-focused pipeline. Comparable as a focused diabetes/endocrine therapy innovator, though differentiated by its inhaled delivery platform.
Direct peers
- Tonghua Dongbao Pharmaceutical: Chinese insulin analog manufacturer competing head-to-head with Gan & Lee in China's VBP insulin market and in emerging-market insulin supply. Closest domestic peer by product overlap (basal/rapid/premixed insulins).
- Wockhardt: Indian pharmaceutical company with a major insulin portfolio (Wosulin, Glaritus, Aspart) serving global biosimilar markets. Comparable product portfolio and emerging-market commercial footprint.
- Biocon: Indian biopharmaceutical company with insulin glargine, insulin aspart and other biosimilars commercialized globally. Comparable on emerging-market insulin biosimilar supply model and licensing-led international expansion.
- United Laboratories International Holdings: Chinese-listed pharmaceutical company with an insulin and biosimilar portfolio, including recombinant human insulin and insulin analogs. Comparable scale and product mix in the China insulin procurement context.
- Novo Nordisk: Global leader in insulin and GLP-1 receptor agonists (semaglutide/Ozempic/Wegovy). Direct competitor to Gan & Lee's insulin franchise and the leading benchmark against which Bofanglutide and GZR4 are being clinically positioned.
Broad incumbents
- Eli Lilly: Diversified major with leading GLP-1/GIP asset tirzepatide (Mounjaro/Zepbound) plus active diabetes pipeline. Comparable on cardiometabolic R&D and on the obesity opportunity Gan & Lee is chasing with Bofanglutide.
- Sanofi: Insulin incumbent (Lantus, Toujeo, Apidra, Insuman) and growing GLP-1 presence. Most directly comparable on the insulin biosimilar/analog business Gan & Lee supplies to Sandoz in Europe.
- Terumo Corporation: Japanese medical device giant with insulin pen needles, injection devices and diabetes care products. Comparable on the drug-delivery device side of Gan & Lee's business (GanleePen, GanleeFine).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Gan & Lee Pharmaceutical social profiles
Digital presenceGan & Lee Pharmaceutical compliance and trust
Trust signalCompliance10 records
Gan & Lee Pharmaceutical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gan & Lee Pharmaceutical leadership team
Management profileNumber of profiles
Profiles7 records
Gan & Lee Pharmaceutical funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gan & Lee Pharmaceutical M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gan & Lee Pharmaceutical
What does Gan & Lee Pharmaceutical do?
Gan & Lee Pharmaceuticals is a Chinese biopharmaceutical company that develops, manufactures, and commercializes recombinant insulin analog products and GLP-1 receptor agonists for diabetes and obesity treatment. The company offers a portfolio of six core insulin products (insulin glargine, insulin lispro, insulin aspart, premixed formulations, and human insulin) along with reusable insulin pens and disposable pen needles, marketed globally through licensing partners and distribution agreements across 23 registered countries.
Is Gan & Lee Pharmaceutical a public or private company?
Gan & Lee Pharmaceutical is a public company. It is classified as public and is currently operating.
When was Gan & Lee Pharmaceutical founded?
Gan & Lee Pharmaceutical was founded in 1998. It employs 1,001 to 5,000 people.
Where is Gan & Lee Pharmaceutical based?
Gan & Lee Pharmaceutical is headquartered in Beijing, China, in the Asia region.
How does Gan & Lee Pharmaceutical make money?
Four revenue lines are on record. Insulin Product Sales are the primary driver. The others are medical Device Sales, licensing and Milestone Payments and technology Transfer and Supply Agreements.
Who are Gan & Lee Pharmaceutical's main competitors?
Emerging players on record are Ypsomed and MannKind Corporation. Direct peers are Tonghua Dongbao Pharmaceutical, Wockhardt, Biocon, United Laboratories International Holdings and Novo Nordisk. Broad incumbents are Eli Lilly, Sanofi and Terumo Corporation.
Does Gan & Lee Pharmaceutical have an API?
No public API is recorded for Gan & Lee Pharmaceutical.
What industry is Gan & Lee Pharmaceutical in?
Gan & Lee Pharmaceutical's product category is Insulin and Diabetes Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIAFAB, Insulin & Analog Biosimilars. Its NAICS code is 325412 and its SIC code is 2834.